Search

The Leptihn lab’s October 2 announcement links a Nature Medicine consensus guideline published September 21, 2026. The primary article describes collaboration involving 20 professional societies, patient advocacy groups and regulatory autho

Workshop at the European Medicines Agency in Amsterdam, with online participation, on Friday 30 October 2026, 09:00 to 18:00 Amsterdam time (CET). It brings together regulators, policymakers, scientists, healthcare professionals, developers

A PHTRP article recounts a Sydney case of multidrug-resistant Klebsiella aerogenes necrotizing pancreatitis and the clinical phage therapy programme that treated it. The team has treated more than 60 patients and conducted more than 200 dia

A University of Colorado Anschutz School of Medicine team led by Breck Duerkop has spent 15 years compiling a library of phages against stubborn gut bacteria, mainly Enterococcus faecalis and E. faecium: more than 30 phages infecting entero

Veterinarians at Mystic Aquarium in Connecticut and the University of Florida treated Jetta, an 11-year-old beluga with chronic pneumonia caused by multidrug-resistant E. coli, with bacteriophages chosen for her strain, delivered partly thr

A Nature Communications study from Stanford University and collaborators used a mouse model of established Pseudomonas aeruginosa wound infection to compare phage route, dose and frequency: topical, but not systemic, delivery reduced wound

The first patient has been enrolled in Part 2 of the Phase 1b/2a clinical trial of SNIPR001, an investigational CRISPR-armed phage therapeutic candidate for preventing E. coli bloodstream infections in hematopoietic stem cell transplant pat

Engineered non-pathogenic E. coli producing lytic phages protected mice against Salmonella infection in a preclinical proof-of-concept study. Nature Microbiology

Inteliphage and Birmingham’s Precision Health Technologies Accelerator will advance PhageXpert, an automated phage susceptibility testing workflow, and support its UK route to market. Precision Health Technologies Accelerator

Armata Pharmaceuticals announced on September 14, 2026 that the US FDA has granted Breakthrough Therapy designation to AP-SA02, its intravenous multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bactere

A CNN report on antimicrobial resistance follows the family of an Indonesian infant whose parents believe resistance played a role in his death, and Mallory Smith, a cystic fibrosis patient who died at 25 from a B. cepacia infection that an

Self-funded PhD project in the University of Manchester's Division of Pharmacy and Optometry (Dr Alain Pluen, Prof Andrew McBain, Dr Robin Curtis, Dr Claudia Igler) to characterise sewage-derived phages, formulate single phages and cocktail

A peer-reviewed expanded-access case report in Clinical Infectious Diseases describes investigational SNIPR001 use in a kidney transplant recipient with progressive multidrug-resistant Escherichia coli malakoplakia, under a single-patient e

On 12 August 2026 the LEO Foundation announced DKK 61.9 million in Research Grants to 16 international projects, including one to Professor Thomas Sicheritz-Pontén (University of Copenhagen); the foundation's grantee record lists his 2026 R

The M. Iashvili Children’s Central Hospital, Georgia’s only tertiary, multidisciplinary pediatric referral hospital, and the George Eliava Institute of Bacteriophages, Microbiology and Virology have signed a memorandum of cooperation. The h

The sixth Japanese Phage Therapy Research Meeting was held jointly with the Japan Biofilm Society’s 40th meeting at Kyorin University on July 31 and August 1, 2026. Kyorin University, Mitaka campus, new lecture building A, 3rd floor, Tokyo

Uruguayan biotechnology company Kinzbio reports the first application of phage therapy at Uruguay's Banco de Prótesis, treating a 30-year-old patient with a hip prosthesis infection caused by an antibiotic-resistant Stenotrophomonas maltoph

Nicholas Smith will lead nuclear imaging and phage pharmacokinetics research and the pharmacology and modelling core at Stanford’s $9.5 million Center for Phage Pharmaceuticals. The NIAID-funded work focuses on optimizing respiratory phage

Inserm's Phage Therapy booster programme, led by its Health technologies and Immunology, inflammation, infectiology and microbiology institutes, will fund a single three-year consortium of 10-12 participants (individual researchers or teams

A McMaster team developed a targeted phage approach to disarm adherent-invasive E. coli linked to inflammation in some people with Crohn’s disease. In controlled experimental models, phages reduced gut inflammation by changing bacterial beh